natgillin/translations-raw huggingface dataset:
The Imraldi vial is a glass vial containing a solution of adalimumab. 
Viala z zdravilom Imraldi je steklena viala, ki vsebuje raztopino adalimumaba.
Vial disposal 
Odstranjevanje viale
After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (Creactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. 
Po zdravljenju z adalimumabom so pri bolnikih z revmatoidnim artritisom opažali hitro znižanje reaktantov akutne faze vnetja (C-reaktivnega proteina (CRP) in hitrosti sedimentacije eritrocitov (SR)) in serumskih citokinov (IL-6) v primerjavi z izhodiščem.
The serum levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA. 
Ugotovljeno je bilo, da so koncentracije prostega adalimumaba (tistega, ki ni vezan na protitelesa proti adalimumabu) v serumu manjše pri bolnikih, ki imajo merljivo raven teh protiteles.
Patients who had been randomised to placebo in Period A were assigned to receive adalimumab 40 mg every week in Period B. 
Bolniki, ki so jih randomizirali na placebo v obdobju A, so v obdobju B prejemali 40 mg adalimumaba vsak teden.
Polyarticular juvenile idiopathic arthritis from 2 years of age 
Poliartikularni juvenilni idiopatski artritis od 2. leta starosti
• Peel the clear package just far enough to expose the white plunger rod, but do not take the syringe out of the package. 
• Odlepite ovojnino ravno toliko, da odkrijete beli nosilec bata, vendar brizge ne vzemite iz ovojnine.
• There have been very rare cases of certain kinds of cancer in children and adults taking Imraldi or other TNFα blockers. 
• Med otroci in odraslimi, ki so jemali zdravilo Imraldi ali druge zaviralce TNFα, so se pojavili zelo redki primeri določenih vrst raka.
The safety and efficacy of adalimumab was assessed in an open-label, multicentre study in 32 children (2<4 years old or aged 4 and above weighing <15 kg) with moderately to severely active polyarticular JIA. 
Varnost in učinkovitost adalimumaba so ocenili v odprti, multicentrični študiji pri 32 otrocih (starih od 2 do < 4 leta ali starih 4 leta ali več in s telesno maso < 15 kg) z zmernim do zelo aktivnim poliartikularnim JIA.
A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1 %[123/178] and 88.8 % [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). 
Od bolnikov, deležnih ponovnega zdravljenja, jih je skupno 76,5 % (218/285) po 16 tednih ponovnega zdravljenja imelo odziv PGA "čisto" ali "minimalno", ne glede na to, ali je med prenehanjem uporabe prišlo do relapsa (69,1 % [123/178] bolnikov, pri katerih je med prenehanjem uporabe prišlo do relapsa, in 88,8 % [95/107]
The combination of Imraldi and anakinra is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”). 
Kombinacija zdravila Imraldi in anakinre ni priporočljiva (glejte poglavje 4.4 “Sočasna uporaba bioloških DMARDS ali antagonistov TNF”).
• Tell your doctor if your child resides or travels in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic. 
• Zdravniku morate povedati, če vaš otrok živi na območju ali potuje v predele, kjer so endemične glivične okužbe, npr. histoplazmoza, kokcidioidomikoza ali blastomikoza.
• low blood measurements for white blood cells, red blood cells and platelet count. 
• nizke krvne vrednosti za bele krvne celice, rdeče krvne celice in trombocite.
Clinical remission Clinical response 
Klinična remisija Klinični odziv
Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 3, P < 0.0001 from log rank test). 
Adalimumab je značilno podaljšal čas do neuspeha zdravljenja v primerjavi s placebom (glejte sliko 3, p < 0,0001 iz testa log-rank).
The incidence of serious infections was 0.04 per patient year in adalimumab treated patients and 0.03 per patient year in placebo and active control-treated patients. 
Incidenca resnih okužb je bila 0,04 na bolnikov-let med bolniki, ki so dobivali adalimumab, in 0,03 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
Disease flare criteria were defined as a worsening of ≥30% from baseline in ≥3 of 6 Paediatric ACR core criteria, ≥2 active joints, 
Merila zagona bolezni so bila opredeljena kot poslabšanje ≥ 3 od 6 osnovnih meril Paediatric ACR za ≥ 30 % v primerjavi z izhodiščem, ≥ 2 aktivna sklepa in izboljšanje ne več kot 1 od 6 meril za > 30 %.
• DO NOT use the white plunger rod to remove the syringe from the package. 
• NE UPORABITE belega nosilca bata, da bi brizgo potegnili iz ovojnine.
In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the adalimumab treated patients and 1.46 per patient year in the placebo and active control-treated patients. 
V kontroliranih preskušanjih, ki podpirajo vlogo za pridobitev dovoljenja za promet, pri odraslih in otrocih je bil delež okužb 1,51 na bolnikov-let med bolniki, ki so dobivali adalimumab, in 1,46 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
Your doctor may recommend temporary discontinuation. 
Zdravnik bo morda priporočil začasno prenehanje uporabe zdravila.
Imraldi may have a minor influence on the ability to drive, cycle or use machines. 
Zdravilo Imraldi ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja strojev.
Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 1, P < 0.0001 from log rank test). 
Adalimumab je značilno podaljšal čas do neuspeha zdravljenja v primerjavi s placebom (glejte sliko 1, p < 0,0001 iz testa log-rank).
PsA study I with 24 week duration, treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50 % were taking methotrexate. 
V njej so zdravili 313 odraslih, ki se niso ustrezno odzvali na terapijo z nesteroidnimi protivnetnimi zdravili; približno 50 % od teh je jemalo metotreksat.
Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged), autoantibody test positive (including double stranded DNA antibody), blood lactate dehydrogenase increased 
pogosti koagulacija in motnje krvavenja (vključno s podaljšanim aktiviranim parcialnim tromboplastinskim časom), prisotnost avtoprotiteles (vključno s protitelesi proti dvovijačni DNA),
• If your child has or develops a demyelinating disease (a disease that affects the insulating layer around the nerves, such as multiple sclerosis), your doctor will decide if he/she should receive or continue to receive Imraldi. 
• Če vaš otrok ima ali se pri njem razvija demielinizirajoča bolezen (bolezen, ki prizadene izolativno plast okoli živcev, kot je multipla skleroza), bo zdravnik presodil, ali lahko dobiva oziroma še nadalje dobiva zdravilo Imraldi.
If you have rheumatoid arthritis and you do not receive methotrexate with your Imraldi therapy, your doctor may decide to give 40 mg adalimumab every week or 80 mg every other week. 
Če imate revmatoidni artritis in hkrati z zdravilom Imraldi ne dobivate metotreksata, vam bo zdravnik morda predpisal 40 mg adalimumaba vsak teden ali 80 mg vsak drugi teden.
Imraldi can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function. 
Zdravilo Imraldi lahko upočasni napredovanje prizadetosti sklepnih hrustancev in kosti, ki jo povzroči bolezen, in izboljša telesno delovanje.
What you need to know before you use Imraldi Do not use Imraldi 
Kaj morate vedeti, preden boste uporabili zdravilo Imraldi Ne uporabljajte zdravila Imraldi
Figure 1: Kaplan-Meier Curves Summarizing Time to Flare in Study nr-axSpA II 
Slika 1: Kaplan-Meierjeve krivulje povzemajo čas do ponovnega zagona bolezni v študiji nr-axSpA II
Imraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate. 
Zdravilo Imraldi je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at week 52 were 15.3±11.4 μg/ml (40/20 mg, weekly) and 6.7±3.5 μg/ml (20/10 mg, weekly). 
Pri bolnikih, ki so prešli z režima vsak drugi teden na režim vsak teden, so bile povprečne (±SD) serumske koncentracije adalimumaba v 52. tednu 15,3 ± 11,4 μg/ml (40/20 mg, tedensko) in 6,7 ± 3,5 μg/ml (20/10 mg, tedensko).
Table 24 Time to Treatment Failure in Studies UV I and UV II 
Čas do neuspeha zdravljenja v študijah UV I in UV II
• Adults with non-infectious uveitis with inflammation affecting the back of the eye 
• odraslih z neinfekcijskim uveitisom, kjer vnetje prizadene zadnji del očesa,
117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through at least 3 years of open-label adalimumab therapy. 
Med odprtim obdobjem zdravljenja z adalimumabom so vsaj 3 leta spremljali 117/276 bolnikov iz študije I Crohnove bolezni ter 272/777 bolnikov iz študij II in III Crohnove bolezni.
In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6 % and 55.7 %, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks). 
Opravljena je bila analiza, v kateri so vse bolnike, ki so izpadli iz študije zaradi neželenih učinkov ali nezadostne učinkovitosti ali jim je bil povečan odmerek, obravnavali kot neodzivne; pri teh bolnikih sta bila po dodatnih 108 tednih odprtega zdravljenja (skupaj 160 tednov) delež odziva PASI 75 69,6 % in delež odziva PGA "čisto" ali "minimalno" 55,7 %.
• If you have or develop demyelinating disease (a disease that affects the insulating layer around the nerves, such as multiple sclerosis), your doctor will decide if you should receive or continue to receive Imraldi. 
• Če imate ali pa se pri vas razvija demielinizirajoča bolezen (bolezen, ki prizadene izolativno plast okoli živcev, kot je multipla skleroza), bo zdravnik presodil, ali lahko dobivate oziroma tudi še nadalje dobivate zdravilo Imraldi.
If you take Imraldi the risk of getting lymphoma, leukaemia, or other cancers may increase. 
Če uporabljate zdravilo Imraldi, se vam lahko poveča tveganje za pojav limfoma, levkemije ali drugih vrst raka.
The safety and efficacy of adalimumab were assessed in two randomized, double-blind placebo-controlled studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). 
Varnost in učinkovitost zdravila adalimumab so ocenili v dveh randomiziranih dvojno slepih, s placebom kontroliranih študijah pri bolnikih z ne-radiografskim aksialnim spondiloartritisom (nraxSpA).
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Imraldi. 
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravila Imraldi pojavijo znaki ali simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
a Patients with at least a partial response to adalimumab 40 mg weekly after 12 weeks of treatment b Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders 
24. teden 36. teden a Bolniki z vsaj delnim odzivom na odmerek 40 mg adalimumaba vsak teden po 12. tednih zdravljenja b Bolniki, ki izpolnjujejo merila, določena v protokolu za izgubo odziva ali brez izboljšanja, so bili izključeni iz študij in so še šteli pod bolnike brez odgovora (“nonresponders”)
The conduct and results of these tests should be recorded on your Patient Reminder Card. 
Izvedbo in rezultate teh preiskav je treba zabeležiti na Opozorilni kartici za bolnika.
Clinical response * p value for Standard Dose versus Low Dose comparison 
* p vrednost za primerjavo standardnega odmerka proti majhnemu odmerku
• DO NOT try to put the clear needle cap back on the needle. 
• NE POSKUŠAJTE prozornega pokrovčka igle znova namestiti na iglo.
Very common Leukopenia (including neutropenia and agranulocytosis), anaemia 
zelo pogosti levkopenija (vključno z nevtropenijo in agranulocitozo),
Imraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. 
Aksialni spondiloartritis brez radiografskega dokaza za AS Zdravilo Imraldi je indicirano za zdravljenje odraslih s hudim aksialnim spondiloartritisom brez radiografskega dokaza za AS, toda z objektivnimi znaki vnetja s povišanimi CRP in/ali MRI, ki so nezadostno reagirali na ali ne prenašajo nesteroidnih protivnetnih zdravil.
DO NOT touch the tip of the syringe. 
NE DOTIKAJTE se konice brizge.
Surgery or dental procedure 
Kirurški poseg ali poseg na zobeh
Methotrexate should be continued during treatment with Imraldi. 
Med zdravljenjem z zdravilom Imraldi je treba še naprej uporabljati metotreksat.
Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score ≤0.5) was significantly higher with adalimumab/methotrexate combination therapy (63.8 % and 61.2 % respectively) compared to methotrexate monotherapy (37.4 % and 33.5 % respectively, p <0.001) and adalimumab monotherapy (50.7 %, p <0.002 and 44.5 %, p <0.001 respectively). 
Po 52 oz. 104 tednih zdravljenja je bil v skupini s kombinirano terapijo z adalimumabom in metotreksatom odstotek bolnikov brez napredovanja bolezni (sprememba prilagojene Sharpove ocene od izhodišča ≤ 0,5) značilno večji (63,8 % oz. 61,2 %) kot v skupinah, ki sta prejemali monoterapijo z metotreksatom (37,4 % in 33,5 %, p < 0,001) ali monoterapijo z adalimumabom (50,7 %, p < 0,002,
In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab-treated patients compared with control patients. 
V eksploracijskem kliničnem preskušanju infliksimaba, antagonista TNF, pri bolnikih z zmerno do hudo kronično obstruktivno pljučno boleznijo (KOPB) so med prejemniki infliksimaba zabeležili več malignomov, večinoma pljuč ali glave in vratu, kot med primerjalnimi bolniki.
The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, and for patients with psoriatic arthritis is 40 mg adalimumab given every two weeks as a single dose. 
Običajni odmerek za odrasle z revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za ankilozirajoči spondilitis in za bolnike s psoriatičnim artritisom je 40 mg adalimumaba vsaka dva tedna v enkratnem odmerku.
Tell your doctor immediately if your child gets symptoms like changes in vision, weakness in arms or legs or numbness or tingling in any part of the body. 
Zdravniku takoj povejte, če vaš otrok dobi simptome, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
Time to Treatment Failure At or After Week 6 in study UV I Primary analysis (ITT) 
Čas do neuspeha zdravljenja v ali po 6. tednu v študiji UV I Primarna analiza (ITT)
Imraldi is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age. 
Zdravilo Imraldi se uporablja za zdravljenje hidradenitis suppurativa pri odraslih in mladostnikih, starejših od 12 let.
At week 52, 42.9 % of patients who received adalimumab/methotrexate combination therapy achieved clinical remission (DAS28 <2.6) compared to 20.6 % of patients receiving methotrexate monotherapy and 23.4 % of patients receiving adalimumab monotherapy. 
Po 52 tednih je klinično remisijo (DAS28 < 2,6) doseglo 42,9 % bolnikov, ki so dobivali kombinirano terapijo z adalimumabom/metotreksatom, 20,6 % bolnikov, ki so dobivali metotreksat v monoterapiji, in 23,4 % bolnikov, ki so dobivali adalimumab v monoterapiji.
Fever, bruising, bleeding or looking pale 
Zvišana telesna temperatura, modrice, krvavitev ali bledica
Hold the syringe steady and press the plunger all the way down. 
Držite injekcijsko brizgo pri miru in potisnite bat do konca navzdol.
Imraldi is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. 
Zdravilo Imraldi je indicirano za zdravljenje hude psoriaze v plakih pri otrocih in mladostnikih od 4. leta starosti, ki so se neustrezno odzvali na ali niso ustrezni kandidati za topikalno zdravljenje in fototerapijo.
In some rare cases, especially if your child is taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening. 
zlasti če vaš otrok uporablja druga zdravila, ki zavirajo imunski sistem, je reaktivacija okužbe s HBV lahko smrtno nevarna.
Sustained Response Sustained Remission Sustained Mucosal Healing Clinical remission is Mayo score ≤2 with no subscore >1; Clinical response is decrease from baseline in Mayo score ≥3 points and ≥30% plus a decrease in the rectal bleeding subscore [RBS] ≥1 or an absolute RBS of 0 or 1; * p<0.05 for adalimumab vs. placebo pairwise comparison of proportions 
Klinični odgovor pomeni znižanje ocene Mayo od začetka za ≥ 3 in ≥ 30 % ter znižanje podocene rektalne krvavitve [RBS] ≥ 1 ali absolutno RBS 0 ali 1; * p < 0,05 za parno primerjavo deležev med adalimumabom in placebom ** p < 0,001 za parno primerjavo deležev med adalimumabom in placebom a Od tistih, ki so izhodiščno prejemali kortikosteroide
Then administer your child's next dose as you would have on the originally scheduled day, had you not forgotten a dose. 
Nato svojemu otroku dajte naslednji odmerek, kot bi ga uporabili po prvotnem urniku injiciranja, če ne bi pozabili odmerka.
Your doctor may prescribe another strength of Imraldi if your child needs a different dose. 
Če vaš otrok potrebuje drugačen odmerek, mu bo zdravnik morda predpisal drugo jakost zdravila Imraldi.
0.8 ml solution for injection in single-use pre-filled syringe (type I glass) with a stainless steel needle, a rigid needle shield, a rubber plunger (bromobutyl), a plunger rod, a safe-shield body and a finger flange for patient use. 
0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi (steklo tipa I) za enkratno uporabo z iglo iz nerjavnega jekla, rigidnim varovalom za iglo, batom iz gume (bromobutilne), steblom bata, zaščitnim ohišjem in prirobnico za bolnikovo uporabo.
Clinical remission 12% Clinical response (CR-100) 
Klinična remisija Klinični odziv (CR-100)
Imraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). 
Poliartikularni juvenilni idiopatski artritis Zdravilo Imraldi je v kombinaciji z metotreksatom indicirano za zdravljenje aktivnega poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti, ki se ne odzovejo ustrezno na eno ali več imunomodulirajočih antirevmatičnih zdravil.
Your doctor will decide if you should receive Imraldi. 
On se bo odločil, ali lahko dobivate zdravilo Imraldi.
Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac Joints and the Spine was maintained in adalimumab-treated patients through week 156 and week 104, respectively. 
Značilno izboljšanje znakov vnetja, merjenih s C-reaktivnim proteinom z veliko občutljivostjo (hs-CRP) in z magnetno resonanco (MRI) sakroiliakalnih sklepov in hrbtenice, se je ohranilo pri bolnikih, zdravljenih z adalimumabom, do 156. tedna oz. do 104. tedna, v tem zaporedju.
Psoriatic arthritis and axial spondyloarthritis including ankylosing spondylitis There is no relevant use of adalimumab in the paediatric population for the indications of ankylosing spondylitis and psoriatric arthritis. 
Psoriatični artritis in aksialni spondiloartritis, vključno z ankiloznim spondilitisom Uporaba adalimumaba pri pediatrični populaciji za indikaciji ankilozni spondilitis in psoriatični artritis ni primerna.
Of 207 patients who were randomised to adalimumab 40 mg every other week, 114 patients continued on adalimumab 40 mg every other week for 5 years. 
Od 207 bolnikov, ki so bili randomizirani na 40 mg adalimumaba vsak drugi teden, jih je 114 nadaljevalo zdravljenje s 40 mg adalimumaba vsak drugi teden še 5 let.
If these medicines do not work well enough, you will be given Imraldi. 
Če ta zdravila ne bodo delovala dovolj dobro, boste dobili zdravilo Imraldi.
Your child should not take Imraldi with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection . 
Zdravila Imraldi vaš otrok ne sme jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Imraldi is used to treat hidradenitis suppurativa in adolescents from 12 years of age. 
Zdravilo Imraldi se uporablja za zdravljenje hidradenitis suppurativa pri mladostnikih, starejših od 12 let.
The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 per 1,000 patient treatment years, respectively (see section 4.4). 
Ugotovljeni delež nemelanomskih rakov je približno 0,2 na 1.000 bolnikov-let zdravljenja in limfomov približno 0,3 na 1.000 bolnikov-let zdravljenja (glejte poglavje 4.4).
Depending on your response, your doctor may increase the dose frequency to 20 mg every week. 
Glede na vaš odziv lahko zdravnik poveča pogostnost odmerjanja na 20 mg vsak teden.
At Week 16, more patients randomised to adalimumab 0.8 mg/kg had positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX. 
V 16. tednu se je več bolnikov, ki so bili randomizirani na adalimumab 0,8 mg/kg, pozitivno odzvalo v smislu učinkovitosti (npr. PASI 75) kot tistih, ki so bili randomizirani na odmerek 0,4 mg/kg vsak drugi teden ali metotreksat.
Maintenance of remission and response rates are presented in Table 23. 
Vzdrževanje remisije in deleže odziva prikazuje preglednica 23.
• While holding the vial adapter firmly, insert the syringe tip into the vial adapter and twist the syringe clockwise with one hand until firm. 
• Medtem ko trdno držite adapter za vialo, vstavite konico brizge v adapter za vialo in z eno roko brizgo zasučite v smeri urnega kazalca, dokler ni trdno nameščena.
Vaccine 
Cepivo
For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of Imraldi should be promptly discontinued. 
Če se bolniku pojavijo znaki ali simptomi, kot so npr. zvišana telesna temperatura, splošno slabo počutje, hujšanje, znojenje, kašelj, dispneja in/ali pljučni infiltrati ali druga sistemska bolezen (s spremljajočim šokom ali brez njega), je treba posumiti na invazivno glivično okužbo.